Nivolumab-relatlimab FDC — Competitive Intelligence Brief

Nivolumab-relatlimab FDC (Nivolumab-relatlimab FDC) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual checkpoint inhibitor (PD-1/LAG-3). Area: Oncology.

phase 3 Dual checkpoint inhibitor (PD-1/LAG-3) PD-1 and LAG-3 Oncology Small molecule

Target snapshot

Nivolumab-relatlimab FDC (Nivolumab-relatlimab FDC) — Bristol-Myers Squibb. This fixed-dose combination blocks both PD-1 and LAG-3 checkpoints on immune cells, releasing dual brakes on anti-tumor immunity.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nivolumab-relatlimab FDC TARGET	Nivolumab-relatlimab FDC	Bristol-Myers Squibb	phase 3	Dual checkpoint inhibitor (PD-1/LAG-3)	PD-1 and LAG-3
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
TAR-210	TAR-210	Janssen Research & Development, LLC	phase 3	Bispecific antibody	PD-1 and LAG-3
AK112, Gemcitabine, Cisplatin	AK112, Gemcitabine, Cisplatin	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy	PD-1 and LAG-3
AK112, Carboplatin, Paxlitaxel	AK112, Carboplatin, Paxlitaxel	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual checkpoint inhibitor (PD-1/LAG-3) class)

1. Bristol-Myers Squibb · 1 drug in this class